Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider David M. Chao Sells 7,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTAGet Free Report) insider David M. Chao sold 7,000 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $17.17, for a total transaction of $120,190.00. Following the transaction, the insider now directly owns 225,007 shares in the company, valued at $3,863,370.19. The trade was a 3.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Centessa Pharmaceuticals Stock Up 1.6 %

Shares of NASDAQ:CNTA opened at $16.77 on Thursday. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -10.96 and a beta of 1.54. The firm’s 50-day simple moving average is $16.46 and its 200-day simple moving average is $16.36. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a fifty-two week low of $7.75 and a fifty-two week high of $19.09.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Morgan Stanley reissued an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $26.00.

Read Our Latest Research Report on CNTA

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new stake in Centessa Pharmaceuticals during the fourth quarter worth about $31,000. Woodline Partners LP boosted its holdings in Centessa Pharmaceuticals by 5.7% during the fourth quarter. Woodline Partners LP now owns 545,645 shares of the company’s stock worth $9,140,000 after buying an additional 29,266 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in Centessa Pharmaceuticals by 33.2% during the fourth quarter. Squarepoint Ops LLC now owns 26,806 shares of the company’s stock worth $449,000 after buying an additional 6,685 shares in the last quarter. Stempoint Capital LP boosted its holdings in Centessa Pharmaceuticals by 667.3% during the fourth quarter. Stempoint Capital LP now owns 641,964 shares of the company’s stock worth $10,753,000 after buying an additional 558,302 shares in the last quarter. Finally, Shay Capital LLC purchased a new stake in Centessa Pharmaceuticals during the fourth quarter worth about $239,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

(Get Free Report)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

Further Reading

Insider Buying and Selling by Quarter for Centessa Pharmaceuticals (NASDAQ:CNTA)

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.